Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Jonas, Sangeetha Venugopal, George Yaghmour, Manu Pandey, Anthony Selwyn Stein, Mikkael Sekeres, Namrata Chandhok, Rasmus Hoeg, Joseph Tuscano, Pamela Becker, Terrence Bradley, Eric Tam, Guido Marcucci, Paul Frankel, Jan Beumer, Steven Gore, Alexey Danilov, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2025-1651

Published: 2025

Journal Articles

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

Brian Jonas, Mehrdad Abedi, Aaron Rosenberg, Naseem Esteghamat, Rasmus Hoeg, Lihong Qi, Eric Tam, Joseph Tuscano, George Yaghmour

Blood (2025) 146 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2025-3356

Published: 2025

Journal Articles

Hyperfractionated cyclophosphamide, bortezomib and dexamethasone for initial treatment of newly diagnosed multiple myeloma with renal dysfunction

Guneet Kaleka, Paul Kaesberg, Brian Jonas, Naseem Esteghamat, Joseph Tuscano, Aaron Rosenberg

Blood (2025) 146 (Supplement 1): 4057.

https://doi.org/10.1182/blood-2025-4057

Published: 2025

Journal Articles

Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC)

Haifaa Abdulhaq, Omar Mahmood, nathan Futoran, Sani Bukari, Calvin Chen, Joseph Tuscano, Aaron Tsumura, Tamer Othman, Elizabeth Brem, Chenchen Niu, Benjamin Heyman, Michelle Don, Azra Borogovac, Matthew Wieduwilt, Maher Albitar

Blood (2025) 146 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2025-1755

Published: 2025

Journal Articles

A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study

Aneeqa Zafar, Naseem Esteghamat, Haifaa Abdulhaq, Shuai Chen, Siyao Li, Paul Kaesberg, Rasmus Hoeg, Aaron Tsumura, Benjamin Heyman, Patricia A. Young, Sani Bukari, Carolyn Mulroney, Herbert Eradat, Aaron Rosenberg, Joseph Tuscano

Blood (2025) 146 (Supplement 1): 5378.

https://doi.org/10.1182/blood-2025-5378

Published: 2025

Journal Articles

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 151.

https://doi.org/10.1182/blood-2025-151

Published: 2025

Journal Articles

Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium

Michael Randall, Wendy Swetzig Dhiman, Chiung-Yu Huang, Charalambos Andreadis, Weiyun Ai, Carrie Ho, Mwanasha Merrill, Madhav Seshadri, Haifaa Abdulhaq, Joseph Tuscano, Nicole Foley, Patricia A. Young, William Pearse, Stephanie Meek, David Kurtz, Michael Spinner

Blood (2025) 146 (Supplement 1): 3630.

https://doi.org/10.1182/blood-2025-3630

Published: 2025

Journal Articles

Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary results from a University of California Malignancy Consortium (UCHMC) Phase II trial, UCDCC#303.

Jacqueline Hsieh-Wong, Naseem Esteghamat, Rasmus Hoeg, Mehrdad Abedi, Sheila Firoozan, Aaron Rosenberg, Ashley Trane, Aneeqa Zafar, Shuai Chen, Siyao Li, Matthew Wieduwilt, Lloyd Damon, Benjamin Heyman, Haifaa Abdulhaq, Elizabeth Brem, Deepa Jeyakumar, Gary Schiller, Joseph Tuscano

Blood (2025) 146 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2025-1966

Published: 2025

Journal Articles

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Michelle A. Quan, Shiliang Zhang, Daria Gaut, Patricia A. Young, Haifaa Abdulhaq, Kevin Shieh, Jack Reid, Elizabeth A. Brem, Benjamin Heyman, Joseph Tuscano

Blood (2022) 140 (Supplement 1): 4851–4852.

https://doi.org/10.1182/blood-2022-163552

Published: 2022

Journal Articles

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse

Daria Gaut, Caspian Oliai, Steven Tsai, Chiung-Yu Huang, Joseph Tuscano, Herbert Eradat, Gary J. Schiller

Blood (2022) 140 (Supplement 1): 12735–12736.

https://doi.org/10.1182/blood-2022-157466

Published: 2022

Journal Articles

Effect of Pesticide Exposure on Non-Hodgkin Lymphoma Incidence and Survival in California

Christina Poh, John D. McPherson, Joseph Tuscano, Qian Li, Arti Parikh-Patel, Christoph F Vogel, Myles Cockburn, Theresa Keegan

Blood (2021) 138 (Supplement 1): 5006.

https://doi.org/10.1182/blood-2021-147012

Published: 2021

Journal Articles

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Hun Ju Lee, Michael Choi, Tanya Siddiqi, Jacqueline Barrientos, William G. Wierda, Iris Isufi, Joseph Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori A. Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Yao Wang, Michael Wang, Catriona Jamieson, Thomas J. Kipps

Blood (2021) 138 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2021-148779

Published: 2021

Journal Articles

A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Tamer Othman, Benjamin Moskoff, Matthew Tenold, Tali Azenkot, Margaret Krackeler, Samantha C Fisch, Laura A. Potter, Paul R. Kaesberg, Jeanna Welborn, Ted Wun, Naseem Esteghamat, Rasmus T. Hoeg, Aaron S. Rosenberg, Mehrdad Abedi, Joseph Tuscano, Brian A. Jonas

Blood (2021) 138 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2021-149276

Published: 2021

Journal Articles

Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center

Christina Poh, MD, Ebaa Alobeidi, MD, Joseph Tuscano, MD, Aaron S Rosenberg, MD, Rasmus T Hoeg, MD, Brian A Jonas, MD PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-136333

Published: 2020

Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141917

Published: 2020

Journal Articles

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Joseph Tuscano, MD, Matthew J. Wieduwilt, MD PhD, Akshay Sudhindra, MD, Jimmy Hwang, PhD, Jesika Reiner, MPH, Michelle Martinelli, Charlie Aoun, BS, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford, Charalambos Andreadis, MD

Blood (2019) 134 (Supplement_1): 2828.

https://doi.org/10.1182/blood-2019-123279

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Samantha C Fisch, BS, Brian A Jonas, MD PhD, Joseph Tuscano, MD, Aaron Seth Rosenberg, MD, Rasmus T Hoeg, MD, Mehrdad Abedi, MD

Blood (2019) 134 (Supplement_1): 3884.

https://doi.org/10.1182/blood-2019-121991

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time

Aaron Seth Rosenberg, MD, Qian Li, MS, Ann M Brunson, MS, Joseph Tuscano, MD, Ted Wun, MD, Theresa H.M. Keegan, PhD MS

Blood (2018) 132 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2018-99-117959

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

Hyperfractionated cyclophosphamide, bortezomib and dexamethasone for initial treatment of newly diagnosed multiple myeloma with renal dysfunction

Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC)

A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse

Effect of Pesticide Exposure on Non-Hodgkin Lymphoma Incidence and Survival in California

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only